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In studies designed to examine the effects of the immune system, recordings of multi-unit
electrical activity (MUA) in the central nervous system were made in the preoptic area/anterior
hypothalamus (POA/AH) and paraventricular nucleus (PVN) ofrats, following sheep red blood
cell (SRBC) immunization. Peak increases in POA/AH MUA were observed on the fifth day
following SRBC sensitization, the day on which serum antibodies were first detected. A
significant increase in paraventricular nucleus (PVN) MUA was also observed on the sixth day.
These changes in POA/AH and PVN MUA were found to be associated with increased plasma
corticosterone levels on day 8. Induction of a second immune response to SRBC evoked a
POA/AH MUA increase of extended duration but reduced amplitude, while administration of
the immunosuppressive drug, cyclophosphamide, prevented both antibody generation and any
increases in POA/AH MUA. These data suggest that activation of the immune system may
providesignals, in theformofchemical messengers, whichareabletoalter neural activity in some
regions of the brain that are important in neuroendocrine regulatory mechanisms. Accordingly,
intracerebroventricular injections ofthymic humoral factor or a-interferon decreased POA/AH
MUA, increased EEG synchronization, anddecreased plasma levels ofcorticosterone. Histamine
and interleukin 1 did not alter POA/AH MUA but decreased EEG synchronization and
increased plasma levels ofcorticosterone.
INTRODUCTION
Although the essential trends in scientific thinking have led to a high degree of
compartmentalization of the living organism into discrete "systems," it has not been
forgotten that there must be interactions between such systems in order to maintain
normal functioning. We are now at a time when we are more informed about, and thus
better able to appreciate, the inherent nature of the interactions between components
ofthe different systems. Thus, the terms neuroimmunomodulation (NIM) and immu-
noendocrinology have arisen to describe the bidirectional interactions thought to exist
between the immune system and thecentral nervous system (CNS) [1,2].
The immune system is probably fully autonomous in its ability for "self versus
non-self' discrimination. The identification ofantigens and thepropagation ofimmune
effector mechanisms are mainly determined by the genome, since these processes can
occur normally in clonal cell lines in vitro. CNS intervention in the activity of the
immune system probably occurs primarilyduring theimmunological processes that are
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categorized as antigen-independent; such as those of ontogeny, cell turnover, cell
migration, and signal sensitivity [2]. These processes are believed to be crucial for the
determination of the intensity and duration of immune responses, thus enabling
defense mechanisms ofthe host to be fully geared.
A great deal of evidence is now available indicating that the CNS is able to exert
modulatory effects upon peripheral immune responses, so that psychological factors
such as stress, e.g., following bereavement [3], personality type, or mental illness may
lead to decreased immunocompetence and increased incidence ofdisease [1,4]. Effects
of immune system activation upon the CNS may be less readily identified, however,
despite the human conditionof"malaise" whendiseased, such feelingsbeinggenerated
within the CNS. How such information reaches the CNS is ofprimary importance to
our understanding of the mechanisms underlying CNS-immune interactions. The
immune system probably generates as yet unidentified signals which are capable of
altering CNS activity, thereby modulating neuroendocrine responses and thus provid-
ing a feedback regulation upon its own activity. This communication, whereby the
CNS provides a fine tuning of the immune system, is thought to be crucial to normal
host defense responses [1,4].
Stress is a major biological phenomenon which is known to alter immune system
function and thus enable the examination of the effects of the CNS upon immune
function, since the physiological effects of stress are mediated via the CNS [5]. The
best-accepted definition of stress is that of any stimulus capable of causing an
activation ofthe hypothalamo-hypophyseal-adrenocortical neuroendocrineaxis, result-
ing in an elevation of circulating plasma glucocorticoid hormone levels [5]. Acute
exposure of experimental animals to stressors may result in a suppression of both
humoral and cellular immune responses [6,7]. On the other hand, repeated exposure to
the same stressor may result in adaptation and, in some cases, an enhanced immune
response [7,8]; for example, the handling ofanimals may enhance immunocompetence
[6]. Furthermore, it has been shown that the immune response may be modified
following classical conditioning paradigms [9] and following the pairing of a neutral
stimulus with an immunosuppressive drug, resulting in a Pavlovian-likeconditioning of
an immunosuppressive response [10]. Other studies have shown that CNS manipula-
tions, such as electrolytic lesions or electrical stimulation ofCNS structures, are able to
cause changes in the activity of the immune system. Anterior hypothalamic lesions
may cause a substantial decrease in the number of nucleated spleen cells and
thymocytes, and in the blastogenic response to mitogens [11], as well as inhibiting
some autoimmune diseases ofthe nervous system [12]. An effect ofcerebral lateraliza-
tion upon immune responses has also been demonstrated; lesions of the left cerebral
neocortex in mice cause a selective depression of cell-mediated responses without
affecting the B-cell response [13]. In another study, it was demonstrated that immune
disorders, such as atopic diseases and autoimmune thyroiditis, are more frequent in
left-handed members ofthe population, and their relatives, than in right-handed people
[14].
Increasingly it has been observed that the immune, nervous, and endocrine systems
share common receptor sites for a variety of neurotransmitters, hormones, neuropep-
tides, and other neuroactive substances, and also the ability to synthesize and secrete
such substances [15-19]. Thus, secretions from differing systems may be expected to
influence components ofthe other systems under various conditions; data to this effect
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are slowly becoming available from a number oflaboratories, as referred to throughout
this text.
Possible routes ofdirect communication between the CNS and the immune system
have been indicated by morphological studies [20,21]. These studies have demon-
strated extensive innervation ofgerminal centers inlymphoid tissues, thereby introduc-
ing the notion ofdirect neural interactions between the CNS and the immune system.
A number ofstudies have now been able todemonstrate electrophysiological responses
within thecentral nervous system following antigenic stimulation or theadministration
ofvarious antigenic agents [22-26], and suchchanges have been shown tooccurduring
the entire course of the immune response [25]. A role for adrenoglucocorticoid
hormones in the suppression of immune responses is well documented and the
immunosuppressive properties ofsuch steroid hormones arefrequently employed in the
clinical context. It is probable that this neuroendocrine axis is of great importance in
the feedback interactions between the immune and nervous systems [27]. For example,
even the normal circadian rhythm ofadrenal glucocorticoid hormone levels in plasma
has been shown to becorrelated with changes in immunecell trafficin manand animals
[28,29], demonstrating the potent effects ofsuch hormones upon the immune system,
the secretions of which are known to be under neural control. Thus, in our studies,
single and multi-unit neuronal responses were recorded in hypothalamic sites known to
be of particular importance in the regulation ofhypothalamo-hypophyseal-adrenocor-
tical activity [30] and which are known also to influence the course of immune
responses and experimentally induced autoimmune diseases [11,12,31]. It is clear
therefore that functional feedback circuits between the immune system and the CNS
exist and that these are probably of considerable physiological significance in normal
regulation of host-defense responses. In our studies, we have tried to describe further
someofthecomponents ofthefeedbackcircuits between theimmunesystem and CNS,
with a particular emphasis upon the regulation of the hypothalamo-hypophyseal-
adrenocortical axis and the role of immunomodulatory factors as mediators of the
bidirectional information flow between the systems.
METHODS
All experiments were performed on adult male rats bearing chronically implanted
recording electrode bundles, implanted under sodium pentobarbital anesthesia, and
consisting of arrays of three 45 ,m Teflon-coated wires which were twisted together
and attached to the terminals ofan appropriate plastic plug. For experiments involving
intracerebroventricular administration of immunomodulatory factors, screws for
recording cortical electroencephalograms (EEG) were implanted over the frontal and
parietal cortices, and a guide cannula was implanted above the lateral ventricle; these
devices were in addition to the recording electrode bundles. The entire assembly was
fixed to the skull with dental cement and the rats allowed to recover for at least one
week before use in any experimental procedures. Daily injections ofsodium penicillin
G were given intramuscularly for three days following the surgery in order to prevent
infection [25,26].
Electrical activity was recorded, using differential recording between electrode
pairs and amplification with standard electrophysiological equipment. Peakmulti-unit
activity (MUA) was discriminated using a voltage-window discriminator, with the
baseline activity selected to be between 10 and 15 Hz [25,26]. The animals were
sensitized with an intraperitoneal injection of a suspension of sheep red blood cells
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(SRBC, 10 percent by volume) in physiological saline; this injection was administered
on the second or third day after recording of the baseline POA/AH and PVN MUA
levels, as observed between the preset voltage-window levels.
EXPERIMENTAL FINDINGS
The First Immune Response
In our first experiments, wehaveemployed aconscious rat model bearingchronically
implanted recording electrodes in the preoptic area/anterior hypothalamus (POA/
AH) and hypothalamic paraventricular nucleus (PVN). The latter area is the primary
site of cells that secrete corticotropin-releasing factor and of vasopressin-secreting
neurones that regulate pituitary adrenocorticotropic hormone (ACTH) secretion.
These two hypothalamic peptides are the principal ACTH regulatory secretagogues
[32].
POA/AH MUA increased from a basal level of 14.65 ± 2.07 Hz to a maximum of
33.06 ± 6.93 Hz (p < 0.005), five days following the SRBC injection; in some animals
maximum POA/AH MUA was recorded on days 4 or 6. This increase was found to be
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correlated with the first appearance of SRBC serum antibodies. Decreases in MUA
were recorded on days 3 and 8 following the sensitization, and basal POA/AH MUA
levels were achieved again by the ninth day (Figs. 1 and 2). Significant increases in
PVN MUA were also recorded after SRBC injection, but these increases were delayed
when compared to those of the POA/AH; the maximum effect occurred on the sixth
day (Fig. 1). Furthermore, in accordance with the works of others [22,33], we were
able to demonstrate increases in plasma corticosterone levels on the eighth day
following SRBC injection [unpublished observations]. We believe that the recorded
changes in PVN MUA, and possibly also those in the POA/AH, may be related to the
alterations in circulating corticosterone levels [25,30].
TheSecond Immune Response
In another group of rats also sensitized with 10 percent SRBC, three weeks before
initiation ofthe same protocol described above, we recorded POA/AH MUA changes
during induction of the secondary immune response to SRBC. The POA/AH MUA
increased significantly between days 4 and 9 following thechallenge, with the maximal
increases recorded on day 6 (Fig. 3). The profile of this second response was different
from that of the first because no decreases in MUA were recorded and the maximal
increase appeared later. The increase was smaller in magnitude, and there were more
days ofsignificantly increased neural activity.
EFFECTS OF IMMUNOSUPPRESSIVE DRUG TREATMENT
Treatment of rats with the immunosuppressive drug cyclophosphamide (25 mg/kg
daily intraperitoneal injection, following each recording period) was able to prevent
both theproduction ofanti-SRBC serumantibodies in response to theSRBCchallenge
and the increase of POA/AH MUA. This result was true for the majority of animals
(five of six); however, a low titer of anti-SRBC antibodies was detected on the tenth
day in one animal. This rat also exhibited an increase in POA/AH MUA on the fifth
day following the SRBC challenge (Table 1). Although many immunosuppressive
drugs, including cyclophosphamide, can increase plasma adrenocorticosteroid levels
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[34,35], it is not the case that the immunosuppressive effects of these drugs are due
solely to their effects upon adrenocortical secretion. It seems likely, therefore, that the
neural responses recorded in the previous studies were a secondary effect of the
immune system activation in response to the antigenic challenge.
EFFECTS OF IMMUNOMODULATORY FACTORS
Antibodies are limited in their ability to cross the blood-brain barrier; therefore, it is
unlikely that these products of the immune system are responsible for the changes in
neural activity following SRBC stimulation. The current consensus of opinion favors
the idea that other soluble products elaborated during the course ofimmune responses
are responsible for the above recorded changes in neural and neuroendocrine activity.
Several laboratories have begun investigating the neural and neuroendocrine effects of
various neuroimmunomodulatory factors. Effects of interleukin 1 (IL-1) and a-
interferon (a-IFN) have been demonstrated in both the clinical and laboratory
situations [36-39]. IL-1, a cytokine released especially by activated monocytes as well
as other cell types including neural glial cells [40,41], is an endogenous pyrogen [42]; it
is capable ofactivating the hypothalamo-hypophyseal-adrenocortical axis [43], induc-
TABLE 1
POA/AH MUA Recorded Following SRBC Immunization in Normal and Cyclophosphamide
Immunosuppressed Rats
% MUA Change Anti-SRBC
Experimental Group (Days 5/6) Titer (Day 10)
SRBC - First response +305 1:128
SRBC - Second response +220
SRBC + CY (5 of6 rats) -1 ND
SRBC + CY (1 of6 rats)a +36 1:32
Rats were immunized with 10 percent SRBC and MUA was recorded every day. Values of the peak
activity of each experimental group are illustrated for comparison. IgM antibodies against SRBC were
detected by hemagglutination test in sera obtained atday 10 post-immunization. ND, not detected.
aOne rat treated with cyclophosphamide (CY) showed a significant change in POA/AH MUA and later
developed serum antibodies toSRBC: see text.
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ing fever probably via an action upon thermosensitive cells within the anterior
hypothalamus [44], and causing release of acute-phase proteins [45]. IL-1 has also
been shown to induce slow-wave sleep [37], although our data suggest that it may be
able to cause a decrease in EEG synchronization, at least in the short term, following
acute central administration [26]. a-IFN is synthesized by activated leukocytes and is
known to exert a number ofdiverse biological effects in addition to its antiviral activity,
including inhibition of DNA synthesis during the lymphoproliferative phase, suppres-
sion of antibody synthesis, and enhancement of natural killer (NK) cell activity [46].
Effects of a-IFN upon the CNS have been recognized in man, and these include
modification ofbehavior [47] and other neurological or psychiatric effects [38]. Effects
ofa-IFN upon EEG and single units in the rat brain have been demonstrated [39], and
there is evidence that such effects may be mediated by endogenous opioid receptor sites
[48]. Effects ofhistamine (HIS) upon arousal [49] and adrenocortical activation [50]
have been recognized for many years, and it is known that this biogenic amine, which is
released by mast cells during allergic responses [51], is also found in neuronal systems
ofthe CNS [49].
In our laboratory, we have investigated the effects of a-IFN, IL-1,HIS, and thymic
humoral factor (THF, [52]) upon cortical EEG, POA/AH MUA, and circulating
corticosterone levels following intracerebroventricular administration of these sub-
stances in conscious rats [26].
Saline did not alter POA/AH MUA, but the total time and duration of synchro-
nized EEG periods was increased in the 45-minute period after injection. a-IFN and
THF were found to reduce POA/AH activity significantly, increase EEG synchroniza-
tion, and decrease plasma corticosterone levels (the latter particularly following daily
administration for three days). HIS and IL-1 did not affect POA/AH MUA, but
decreased the amount of EEG synchronization and increased plasma corticosterone
levels. The results are summarized in Figs. 4, 5, and 6, and they demonstrate that
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FIG. 4. POA/AH MUA recorded before (Pre-Inj.), and 15 minutes and 45
minutes after intracerebroventricular injection of immunomodulatory factors as indi-
cated. The number of test periods with each substance are shown at the base of each
column. Significance levels were obtained by comparison with the pre-injection dis-
charge rate. a,p < 0.05; d,p < 0.005.
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several factors elaborated by the immune system areable to alter EEG activity, plasma
levels ofadrenocortical hormones, and multi-unit activity in an area ofthe brain that is
known to be influenced by immune responses, and which modulates both immune and
neuroendocrine secretory activity, vide supra.
DISCUSSION
The results ofour studies confirm and extend the data ofother authors and indicate
that, during the course of normal immune responses, related changes in electrical
activity in the brain occur, particularly in areas concerned with neuroendocrine
regulatory mechanisms [22-26]. These changes appear to follow the course of the
peripheral immune response, at least in terms ofantibody production, and they may be
altered by prior exposure to the antigen used. Some of these changes (in the PVN)
appear to be related directly to the central neural regulation of the hypothalamo-
hypophyseal-adrenocortical axis [30]. That immunosuppressive drug treatment is able
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(u upon basal plasma corticosterone levels
Xo in rats following icy administration of
E the factors indicated. Corticosterone lev-
< 2- L - ~~~~~~~~~~els measured45minutesfollowingacute E_rrRS O ~~~~~~~~~(open bars) or chronic administration
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0- -Q 10 -ll Significance levels obtained by compar-
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to prevent the neurophysiological changes supports the concept that humoral signals,
arising from the activated immune system, mediate thesechanges in neural activity. In
this context, some identified immune system factors were found to have effects upon
the EEG, POA/AH MUA, and plasma adrenocortical hormone levels, although the
physiological significance ofthe data obtained remains to be clarified further.
Speculation concerning the physiological significance of some ofthe effects demon-
strated maybemade. Forexample, botha-IFN andTHF, which haveimmunostimula-
tory properties [46,52], were found to decrease plasma corticosterone levels, increases
in which are usually able to cause immunosuppression [27-29, 53-56]. This finding
suggests that thesefactors exert a positive feedbackeffect upon theirown actions. Thus
THF, secreted by the thymus gland, inhibits basal corticosteroid secretion, permitting
an up-regulation of thymic activity, which is usually suppressed by glucocorticoid
hormones [55,56], and potentiating its other actions upon the immune system [52]. On
the other hand, activation of the hypothalamo-hypophyseal-adrenocortical axis by
histamine, released during allergic responses [50,51], may be able to cause confine-
ment of the response to the site of insult, thus preventing the development of a
generalized anaphylactic reaction, by virtue ofthe anti-inflammatory effects ofgluco-
corticoid hormones.
Although the studies have demonstrated extensive influences of immune activity
upon the central nervous system, the sites of action and the mechanisms of induction
and action, as well as the physiological significance of the recorded effects, require
further study. In particular, the elucidation ofthe factors involved in the neurophysio-
logical responses await identification, as do the responsive neural elements and their
efferent targets.
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